
1. j infect dis. 2001 oct 15;184(8):983-91. epub 2001 aug 30.

secondary mutations protease region human immunodeficiency virus and
virologic failure drug-naive patients treated protease inhibitor-based
therapy.

perno cf(1), cozzi-lepri a, balotta c, forbici f, violin m, bertoli a, facchi g, 
pezzotti p, cadeo g, tositti g, pasquinucci s, pauluzzi s, scalzini a, salassa b,
vincenti a, phillips an, dianzani f, appice a, angarano g, monno l, ippolito g,
moroni m, d' arminio monforte a; italian cohort naive antiretroviral (i.co.n.a.) 
study group.

author information: 
(1)istituto di ricovero e cura carattere scientifico l. spallanzani, and
department experimental medicine, university rome tor vergata, 00133 rome, 
italy. cf.perno@uniroma2.it

comment in
    j infect dis. 2002 may 1;185(9):1376; author reply 1376-7.
    j infect dis. 2002 jun 15;185(12):1844-6.

the role mutations protease (pr) reverse-transcriptase (rt) human
immunodeficiency virus (hiv) predicting virologic failure assessed 248 
antiretroviral-naive hiv-positive patients began pr inhibitor-containing
antiretroviral regimen. genotypic testing performed plasma samples stored 
before start therapy. twenty-seven patients (10.9%) mutations the
rt, 5 (2%) carried primary mutations pr, 131 (52.8%) showed only
secondary pr mutations. virologic failure week 24 occurred 62 (25.0%) of
248 patients. statistically significant correlation virologic
failure number pr mutations (p= .04, chi(2) test). mutations codons
10 36 pr (present 39.3% 40.0% patients treatment failed,
respectively) identified stepwise logistic regression strongest
predictors virologic failure (odds ratio, 2.20; 95% confidence interval,
1.30-3.75; p= .004). confirmed independent studies, result may justify
the increased use hiv genotyping drug-naive patients requiring
antiretroviral therapy.

doi: 10.1086/323604 
pmid: 11574912  [indexed medline]

